You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
啟明醫療-B(02500.HK):將以不超4.93億元收購諾誠醫療100%股權
格隆匯 10-10 19:58

格隆匯10月10日丨啟明醫療-B(02500.HK)公佈,誠如2021年8月13日的公吿披露,內容有關公司擬收購杭州諾誠醫療科技有限公司(“諾誠醫療”)的股份,以獲得其用於治療肥厚型心肌病(“HCM”)的Liwen RF®射頻消融系統。

2021年9月30日,公司已透過其一間於中國註冊成立的全資附屬公司訂立了一份對諾誠醫療的股權收購協議。根據協議,集團將以最高不超過4.93億元人民幣的對價,向諾誠醫療的現有股東收購其100%股權,並基於約定的里程碑事件完成情況,向諾誠醫療的股東有條件分次支付對價。

公吿顯示,諾誠醫療為一間於中國註冊成立的有限責任公司,成立於2017年,由德諾醫療集團孵化,系一家專注於肥厚型心肌病治療器械研發的高新技術企業,已開發出世界首個應用於肥厚型心肌病經心肌活檢、消融的系統,已進入臨牀試驗階段。

董事會深信,此次收購將顯著提升公司產品管線的創新性,並在結構性心臟病診療領域發揮商業化協同作用,鞏固競爭優勢。基於公司與德諾醫療集團的長期戰略合作關係,雙方將繼續在結構性心臟病領域進行深度的合作和整合。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account